Skip to main content
. 2018 Mar 13;4(1):1–7. doi: 10.1016/j.cdtm.2017.12.001

Table 1.

The incidence of ICI treatment-related AEs in GI cancers.

Study ICIs Cancer type Decreased appetite (%) Nausea (%) Diarrhea (%) Colitis (%) Others (%)
CheckMate 14221 Nivo (3)a, n = 74 CRC 9.5 21.6 1.4 4.1 (Stomatitis)
2.7 (Abdominal pain)
1.4 (Esophagitis)
1.4 (Gastritis)
KEYNOTE-01222 Pembro, n = 39 GC 12.8
KEYNOTE-059 cohort 123 Pembro, n = 259 GC 7.3 6.9 6.6 2.3
ATTRACTION-224 Nivo, n = 330 GC, EGJ 4.8 4.2 7.0 0.6
Placebo, n = 163 4.3 2.5 1.9 0.0
CheckMate 03225 Nivo (3)a, n = 59 GC, EC, EGJ 15.3 15.3
Nivo (3)a + Ipi (1)a, n = 52 5.8 9.6
Nivo (1)a + Ipi (3)a, n = 49 10.2 30.6
Desai et al 201726 BGB-A317, n = 55 GC, EC 16.4 1.8 14.5 (Dysphagia)
KEYNOTE-02827 Pembro, n = 23 EC 13.0
Kudo et al 201728 Nivo, n = 65 ESCC 9.2 13.8 1.5 (Constipation)
Ralph et al 201031 Treme, n = 18 GC, EAC 16.7 27.8 5.6
KEYNOTE-059 cohort 232 Pembro+5-FU/CAPE + CDDP, n = 25 GC 4.0
Moehler et al 201633 Ipi, n = 57 GC, EGJ 24.6
CheckMate 14234 Nivo (3)a + Ipi (1)a, n = 30 CRC 20.0 43.3
Nivo (3)a + Ipi (1)a, n = 10 20.0 20.0 10.0 (Vomiting)
Nivo (1)a + Ipi (3)a, n = 10 30.0 40.0 30.0 (Vomiting)

ICI: immune-checkpoint inhibitor; AE: adverse event; GI: gastrointestinal; Pembro: pembrolizumab; Nivo: nivolumab; Ipi: ipilimumab; Treme: tremelimumab; 5-FU: 5-fluorouracil; CAPE: capecitabine; CDDP: cisplatin; CRC: colorectal cancer; GC: gastric cancer; EGJ: esophagogastric junction; EC: esophageal carcinoma; EAC: esophageal adenocarcinoma; ESCC: esophageal squamous-cell carcinoma; −: not applicable.

a

The number in the parenthesis indicated the dose of Nivo or Ipi: “3” represented “3 mg/kg” and “1” represented “1 mg/kg”.